Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-04-30T13:07:41.458Z Has data issue: false hasContentIssue false

12 - Opioid side effects and management

from SECTION IV - PHARMACOLOGICAL TREATMENT

Published online by Cambridge University Press:  06 July 2010

By
MAXINE DE LA CRUZ  and
EDUARDO D. BRUERA
Edited by
Eduardo D. Bruera  and
Russell K. Portenoy
MAXINE DE LA CRUZ
Affiliation:
The University of Texas M. D. Anderson Cancer Center
EDUARDO D. BRUERA
Affiliation:
The University of Texas M. D. Anderson Cancer Center
Eduardo D. Bruera
Affiliation:
University of Texas, Houston
Russell K. Portenoy
Affiliation:
Albert Einstein College of Medicine, New York
Get access

Summary

Introduction

The majority of cancer patients (approximately 80%) develop pain before they die. Pain in cancer patients is often underdiagnosed, and inadequate treatment with opioid analgesics is well documented. Many factors influence pain management in this patient group. Inappropriate and suboptimal education of physicians and other health care professionals has been identified as the major barrier to adequate opiate use. In developing countries, a further issue is reduced availability of opioids due to financial limitations and government regulations.

As a result of a major educational effort by a number of organizations, including the World Health Organization, the International Association for the Study of Pain, and the American Society of Clinical Oncology, opioid use has improved very significantly in developed countries during the past two decades. The results of such efforts have been quite variable. However, in many regions of the world, progress has been made, with opioids being used in higher doses and at earlier stages in palliative care. Cancer patients, who now have earlier exposure to opioids and generally have treatment with higher dosages, are better managed than in the past. This highly desirable increase in the use of opioids, combined with increased vigilance, has resulted in increased detection of several side effects, most notably neurotoxicity. With this increase in opioid use and the improvement in identification of adverse effects, management strategies for dealing with these unwanted effects have been developed and augmented.

Type
Chapter
Information
Cancer Pain
Assessment and Management
 , pp. 230 - 254
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Portenoy, RK. Cancer pain. Epidemiology and syndromes. Cancer 63(11 Suppl):2298–307, 1989.3.0.CO;2-A>CrossRefGoogle ScholarPubMed
,World Health Organization. Expert Committee report 1990. Cancer pain relief and palliative care. Technical Series 804. Geneva: World Health Organization, 1990.Google Scholar
Cleeland, CS, Gronin, R, Hatfield, AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330:592–6, 1994.CrossRefGoogle ScholarPubMed
Bruera, E, Brenneis, C, Michaud, M, MacDonald, RN. Influence of the pain and symptom control team (PSCT) on the patterns of treatment of pain and other symptoms in a cancer center. J Pain Symptom Manage 4:112–16, 1989.CrossRefGoogle Scholar
Roenn, JH, Cleeland, CS, Gonin, R, et al. Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med 119:121–6, 1993.CrossRefGoogle Scholar
Cherny, NJ, Ho, MN, Bookbinder, M, et al. Cancer pain: knowledge and attitudes of physicians at a cancer center [abstract]. Proc Am Soc Clin Oncol 12:434, 1994.Google Scholar
,World Health Organization. Cancer pain relief, 2nd ed. Report of a WHO Expert Committee. Geneva: World Health Organization, 1996.Google Scholar
Zenz, M, Willweber-Strumpf, A. Opiophobia and cancer pain in Europe. Lancet 341:1075–6, 1993.CrossRefGoogle Scholar
Bruera, E, Macmillan, K, Hanson, J, MacDonald, RN. Palliative care in a cancer center: results in 1984 versus 1987. J Pain Symptom Manage 5:1–5, 1990.CrossRefGoogle Scholar
Sjogren, P, Banning, AM, Christensen, CB, Pedersen, O. Continuous reaction time after single dose, long-term oral and epidural opioid administration. Eur J Anaesthesiol 11:95–100, 1994.Google ScholarPubMed
Bruera, E, Macmillan, K, Hanson, J, MacDonald, RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 39:13–16, 1989.CrossRefGoogle ScholarPubMed
Vainio, A, Ollila, J, Matikainen, E, et al. Driving ability in cancer patients receiving long-term morphine analgesia [see comments]. Lancet 346:667–70, 1995.CrossRefGoogle Scholar
Banning, A, Sjogren, P, Kaiser, F. Reaction time in cancer patients receiving peripherally acting analgesics alone or in combination with opioids. Acta Anaesthesiol Scand 36:480–2, 1992.CrossRefGoogle ScholarPubMed
Banning, A, Sjogren, P. Cerebral effects of long-term oral opioids in cancer patients measured by continuous reaction time. Clin J Pain 6:91–5, 1990.CrossRefGoogle ScholarPubMed
Saarialho-Kere, U, Mattila, MJ, Paloheimo, M, Seppala, T. Psychomotor, respiratory and neuroendocrinological effects of buprenorphine and amitriptyline in healthy volunteers. Eur J Clin Pharmacol 33:139–46, 1987.CrossRefGoogle ScholarPubMed
MacDonald, FC, Gough, KJ, Nicoll, RA, Dow, RJ. Psychomotor effects of ketorolac in comparison with buprenorphine and diclofenac [see comments]. Br J Clin Pharmacol 27:453–9, 1989.CrossRefGoogle Scholar
Sjogren, P, Banning, A. Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids. Pain 39:5–11, 1989.CrossRefGoogle ScholarPubMed
Sjogren, P, Banning, AM, Larsen, TK, et al. Postural stability during long-term treatment of cancer patients with epidural opioids. Acta Anaesthesiol Scand 34:410–12, 1990.CrossRefGoogle ScholarPubMed
Gordon, N.Reaction times of methadone treated ex-heroin addicts. Psychopharmacologia 16:337–44, 1976.CrossRefGoogle Scholar
Lombardo, WK, Lombardo, B, Goldstein, A. Cognitive functioning under moderate and low dosage methadone maintenance. Int J Addict 11:389–401, 1976.CrossRefGoogle ScholarPubMed
Rothenberg, S, Schottenfeld, S, Meyer, RE, et al. Performance differences between addicts and non-addicts. Psychopharmacology 52:299–307, 1977.CrossRefGoogle ScholarPubMed
Joo, S. Methadone substitution and driver ability: research findings and conclusions from a discussion of experts. J Traffic Med 22:101–3, 1994.Google Scholar
Fainsinger, RL, Miller, MJ, Bruera, E. Morphine intoxication during acute reversible renal insufficiency [letter; comment]. J Palliat Care 8:52–3, 1992.Google Scholar
Fainsinger, R, Schoeller, T, Boiskin, M, Bruera, E. Palliative care round: cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care 9:53–5, 1993.Google Scholar
Bruera, E, Chadwick, S, Weinlick, A, MacDonald, N. Delirium and severe sedation in patients with terminal cancer [letter]. Cancer Treat Rep 71:787–8, 1987.Google Scholar
Bruera, E, Fainsinger, RL, Schoeller, T, Ripamonti, C. Rapid discontinuation of hypnotics in terminal cancer patients: a prospective study. Ann Oncol 7:855–6, 1996.CrossRefGoogle ScholarPubMed
Pargeon, KL, Hailey, BJ. Barriers to effective cancer pain management: a review of the literature. J Pain Symptom Manage 18:358–68, 1999.CrossRefGoogle ScholarPubMed
Ward, SE, et al. Patient-related barriers to management of cancer pain. Pain 52:319–24, 1993.CrossRefGoogle ScholarPubMed
Manfredi, PL, Ribeiro, S, Chandler, SW, Payne, R. Inappropriate use of naloxone in cancer patients with pain. J Pain Symptom Manage 11:131–4, 1996.CrossRefGoogle ScholarPubMed
Bruera, E, Schoeller, T, Wenk, R, et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage 10:348–55, 1995.CrossRefGoogle ScholarPubMed
Bruera, E, Watanabe, S. Psychostimulants as adjuvant analgesics. J Pain Symptom Manage 9:412–15, 1994.CrossRefGoogle ScholarPubMed
Forrest, WH Jr, Brown, BW Jr, Brown, CR, et al. Dextroamphetamine with morphine for the treatment of postoperative pain. N Engl J Med 296:712–15, 1977.CrossRefGoogle ScholarPubMed
Bruera, E, Brenneis, C, Chadwick, S, et al. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 71:67–70, 1987.Google ScholarPubMed
Bruera, E, Fainsinger, R, MacEachern, T, Hanson, J. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 50:75–7, 1992.CrossRefGoogle ScholarPubMed
Wilwerding, MB, Loprinzi, CL, Mailliard, JA, et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer 3:135–8, 1995.CrossRefGoogle ScholarPubMed
Fernandez, F, Adams, F, Levy, JK, et al. Cognitive impairment due to AIDS-related complex and its response to psychostimulants. Psychosomatics 29:38–46, 1988.CrossRefGoogle ScholarPubMed
Webster, L, Andrews, M, Stoddard, G. Modafinil treatment of opioid-induced sedation. Pain Med 4:135–40, 2003.CrossRefGoogle ScholarPubMed
Rozans, M, et al. Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol 20:335–9, 2002.CrossRefGoogle ScholarPubMed
Wilens, TE, Biederman, J. The stimulants. Psychiatr Clin North Am 15:191–222, 1992.Google ScholarPubMed
Laska, EM, et al. Caffeine as an analgesic adjuvant. JAMA 251:1711–18, 1984.CrossRefGoogle ScholarPubMed
Broughton, RJ, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 49:444–51, 1997.CrossRefGoogle ScholarPubMed
Czeisler, CA, et al. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med 353:476–86, 2005.CrossRefGoogle ScholarPubMed
Keating, GM, Raffin, MJ. Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder. CNS Drugs 19:785–803, 2005.CrossRefGoogle ScholarPubMed
Eisenach, JC. Muscarinic-mediated analgesia. Life Sci 64:549–54, 1999.CrossRefGoogle ScholarPubMed
Rada, P, et al. Systemic morphine simultaneously decreases extracellular acetylcholine and increases dopamine in the nucleus accumbens of freely moving rats. Neuropharmacology 30:1133–6, 1991.CrossRefGoogle ScholarPubMed
Osman, NI, Baghdoyan, HA, Lydic, R. Morphine inhibits acetylcholine release in rat prefrontal cortex when delivered systemically or by microdialysis to basal forebrain. Anesthesiology 103:779–87, 2005.CrossRefGoogle ScholarPubMed
Slatkin, NE, Rhiner, M, Bolton, TM. Donepezil in the treatment of opioid-induced sedation: report of six cases. J Pain Symptom Manage 21:425–38, 2001.CrossRefGoogle ScholarPubMed
Slatkin, N, Rhiner, M. Treatment of opioid-induced delirium with acetylcholinesterase inhibitors: a case report. J Pain Symptom Manage 27:268–73, 2004.CrossRefGoogle ScholarPubMed
Bruera, E, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manage 26:1049–54, 2003.CrossRefGoogle ScholarPubMed
Slatkin, NE, Rhiner, M. Treatment of opiate-related sedation: utility of the cholinesterase inhibitors. J Support Oncol 1:53–63, 2003.Google ScholarPubMed
Twycross, RG, Lack, SA. Control of alimentary symptoms in far advanced cancer. London: Churchill Livingstone, 1986, pp 166–207.Google Scholar
Hunt, R, Fazekas, B, Thorne, D, Brooksbank, M. A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. J Pain Symptom Manage 18:111–19, 1999.CrossRefGoogle ScholarPubMed
Mancini, I, Hanson, J, Neumann, C, Bruera, E. Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study. J Palliat Med 3:49–56, 2000.CrossRefGoogle ScholarPubMed
Manara, L, et al. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Ther 237:945–9, 1986.Google ScholarPubMed
Brown, NJ, Coupar, IM, Rumsey, RD. The effect of acute and chronic administration of morphine and morphine withdrawal on intestinal transit time in the rat. J Pharm Pharmacol 40:844–8, 1988.CrossRefGoogle ScholarPubMed
Luca, A, Coupar, IM. Insights into opioid action in the intestinal tract. Pharmacol Ther 69:103–15, 1996.CrossRefGoogle ScholarPubMed
Portenoy, RK. Constipation in the cancer patient: causes and management. Med Clin North Am 71:303–11, 1987.CrossRefGoogle ScholarPubMed
Manara, L, Bianchetti, A. The central and peripheral influences of opioids on gastrointestinal propulsion. Ann Rev Pharmacol Toxicol 25:249–73, 1985.CrossRefGoogle ScholarPubMed
Bruera, E, Suarez-Almazor, M, Velasco, A, et al. The assessment of constipation in terminal cancer patients admitted to a palliative care unit: a retrospective review. J Pain Symptom Manage 9:515–19, 1994.CrossRefGoogle ScholarPubMed
Starreveld, JS, Pols, MA, Wijk, HJ, et al. The plain abdominal radiograph in the assessment of constipation. Gastroenterology 28:335–8, 1990.Google ScholarPubMed
Smith, RG, Lewis, S. The relationship between digital rectal examination and abdominal radiographs in elderly patients. Age Ageing 19:142–3, 1990.CrossRefGoogle ScholarPubMed
McKay, LF, Smith, RG, Eastwood, MA, et al. An investigation of colonic function in the elderly. Age Ageing 12:105–10, 1983.CrossRefGoogle ScholarPubMed
Hardcastle, JD, Wilkins, JL. The action of sennosides and related compounds on human colon and rectum. Gut 11:1038–42, 1970.CrossRefGoogle ScholarPubMed
Mancini, IL, Bruera, E. Constipation in advanced cancer patients. Support Care Cancer 6:364, 1998.CrossRefGoogle ScholarPubMed
Bruera, E, Brenneis, C, Michaud, M, MacDonald, N. Continuous Sc infusion of metoclopramide for treatment of narcotic bowel syndrome [letter]. Cancer Treat Rep 71:1121–2, 1987.Google Scholar
Kreek, MJ, Schaefer, RA, Hahn, EF, Fishman, J. Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet 1:261–2, 1983.CrossRefGoogle ScholarPubMed
Culpepper-Morgan, JA, Inturrisi, CE, Portenoy, RK, et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 52:90–5, 1992.CrossRefGoogle ScholarPubMed
Sykes, NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 10:135–44, 1996.CrossRefGoogle ScholarPubMed
Meissner, W, Schmidt, U, Hartmann, M, et al. Oral naloxone reverses opioid-associated constipation. Pain 84:105–9, 2000.CrossRefGoogle ScholarPubMed
Tavani, A, et al. Morphine is most effective on gastrointestinal propulsion in rats by intraperitoneal route: evidence for local action. Life Sci 27:2211–17, 1980.CrossRefGoogle ScholarPubMed
Murphy, DB, et al. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology 87:765–70, 1997.CrossRefGoogle ScholarPubMed
Yuan, CS, et al. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 59:469–75, 1996.CrossRefGoogle ScholarPubMed
Thomas, J, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 358:2332–43, 2008.CrossRefGoogle ScholarPubMed
Yuan, CS, Foss, JF, O'Connor, M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 283:367–72, 2000.CrossRefGoogle ScholarPubMed
Yuan, CS, Foss, JF. Oral methylnaltrexone for opioid-induced constipation [letter]. JAMA 284:1383–4, 2000.CrossRefGoogle Scholar
Portenoy, RK, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 35:458–68, 2008.CrossRefGoogle ScholarPubMed
Lang, L. The Food and Drug Administration approves methylnaltrexone bromide for opioid-induced constipation. Gastroenterology 135:6, 2008.Google ScholarPubMed
Wenk, R, Bertolino, M, Ochoa, J, et al. Laxative effects of fresh baker's yeast [letter]. J Pain Symptom Manage 19:163–4, 2000.CrossRefGoogle Scholar
Joishy, SK, Walsh, D. The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: application in bone metastases and the opioid bowel syndrome. J Pain Symptom Manage 16:334–9, 1998.CrossRefGoogle ScholarPubMed
Frantzides, CT, Lianos, EA, Wittmann, D, et al. Prostaglandins and modulation of small bowel myoelectric activity. Am J Physiol 262(3 Pt 1):G488–97, 1992.Google ScholarPubMed
Thor, P, Konturek, JW, Konturek, SJ, Anderson, JH. Role of prostaglandins in control of intestinal motility. Am J Physiol 248(3 Pt 1):G353–9, 1985.Google ScholarPubMed
Allan, SG. Nausea and vomiting. In: Doyle, D, Hanks, GW, MacDonald, N, eds. Oxford textbook of palliative medicine. Oxford: Oxford University Press, 1993 pp 282–90.Google Scholar
Clarke, RS. Nausea and vomiting. Br J Anaesth 56:19–27, 1984.CrossRefGoogle ScholarPubMed
Campora, E, et al. The incidence of narcotic-induced emesis. J Pain Symptom Manage 6:428–30, 1991.CrossRefGoogle ScholarPubMed
Hagen, NA, Foley, KM, Cerbone, DJ, et al. Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage 6:125–8, 1991.CrossRefGoogle ScholarPubMed
Bruera, E, Seifert, L, Watanabe, S, et al. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen [see comments]. J Pain Symptom Manage 11:147–53, 1996.CrossRefGoogle Scholar
Bruera, ED, MacEachern, TJ, Spachynski, KA, et al. Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer 74:3204–11, 1994. [Published erratum appears in Cancer 75:1733, 1995.]3.0.CO;2-G>CrossRefGoogle ScholarPubMed
Bruera, E, Belzile, M, Neumann, C, et al. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage 19:427–35, 2000.CrossRefGoogle ScholarPubMed
Gan, TJ, et al. Preoperative parenteral parecoxib and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery. Anesth Analg 98:1665–73, 2004.CrossRefGoogle ScholarPubMed
Wamsley, JK, Lewis, MS, Young, WS 3rd, Kuhar, MJ. Autoradiographic localization of muscarinic cholinergic receptors in rat brainstem. J Neurosci 1:176–91, 1981.CrossRefGoogle ScholarPubMed
Palacios, JM, Wamsley, JK, Kuhar, MJ. The distribution of histamine H1-receptors in the rat brain: an autoradiographic study. Neuroscience 6:15–37, 1981.CrossRefGoogle ScholarPubMed
Bruera, ED, Roca, E, Cedaro, L, et al. Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep 67:381–3, 1983.Google ScholarPubMed
Cashman, JN, Dolin, SJ. Respiratory and haemodynamic effects of acute postoperative pain management: evidence from published data. Br J Anaesth 93:212–23, 2004.CrossRefGoogle ScholarPubMed
Shapiro, A, et al. The frequency and timing of respiratory depression in 1524 postoperative patients treated with systemic or neuraxial morphine. J Clin Anesth 17:537–42, 2005.CrossRefGoogle ScholarPubMed
Florez, J, McCarthy, , Borison, HL. A comparative study in the cat of the respiratory effects of morphine injected intravenously and into the cerebrospinal fluid. J Pharmacol Exp Ther 163:448–55, 1968.Google ScholarPubMed
Walsh, TD. Opiates and respiratory function in advanced cancer. Recent Results Cancer Res 89:115–17, 1984.CrossRefGoogle ScholarPubMed
Etches, RC. Respiratory depression associated with patient-controlled analgesia: a review of eight cases. Can J Anaesth 41:125–32, 1994.CrossRefGoogle ScholarPubMed
Pasero, C, McCaffery, M. Reversing respiratory depression with naloxone. Am J Nurs 100:26, 2000.Google ScholarPubMed
Pasero, CL, McCaffery, M. Avoiding opioid-induced respiratory depression. Am J Nurs 94:24–30; quiz 30–1, 1994.CrossRefGoogle ScholarPubMed
Osborne, RJ, Joel, SP, Slevin, ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J (Clin Res Ed) 292:1548–9, 1986.CrossRefGoogle ScholarPubMed
Hunt, G, Bruera, E. Respiratory depression in a patient receiving oral methadone for cancer pain. J Pain Symptom Manage 10:401–4, 1995.CrossRefGoogle Scholar
Oneschuk, D, Bruera, E. Respiratory depression during methadone rotation in a patient with advanced cancer. J Palliat Care 16:50–4, 2000.Google Scholar
Borgbjerg, FM, Nielsen, K, Franks, D. Experimental pain stimulates respiration and attenuates morphine-induced respiratory depression: controlled study in human volunteers. Pain 64:123–8, 1996.CrossRefGoogle ScholarPubMed
Walsh, TD, Rivera, NI, Kaiko, R. Oral morphine and respiratory function amongst hospice inpatients with advanced cancer. Support Care Cancer 11:780–4, 2003.CrossRefGoogle ScholarPubMed
Hanks, GW, Twycross, RG, Lloyd, JW. Unexpected complication of successful nerve block. Morphine induced respiratory depression precipitated by removal of severe pain. Anaesthesia 36:37–9, 1981.CrossRefGoogle ScholarPubMed
Wells, CJ, Lipton, S, Lahuerta, J. Respiratory depression after percutaneous cervical anterolateral cordotomy in patients on slow-release oral morphine [letter]. Lancet 1:739, 1984.CrossRefGoogle Scholar
Cousins, MJ, Mather, . Intrathecal and epidural administration of opioids. Anesthesiology 61:276–310, 1984.Google ScholarPubMed
Ballantyne, JC, Loach, AB, Carr, DB. Itching after epidural and spinal opiates. Pain 33:149–60, 1988.CrossRefGoogle ScholarPubMed
Barke, KE, Hough, LB. Simultaneous measurement of opiate-induced histamine release in the periaqueductal gray and opiate antinociception: an in vivo microdialysis study. J Pharmacol Exp Ther 266:934–42, 1993.Google Scholar
Barke, KE, Hough, LB. Opiates, mast cells and histamine release. Life Sci 53:1391–9, 1993.CrossRefGoogle ScholarPubMed
Horta, ML, Ramos, L, Goncalves, ZR. The inhibition of epidural morphine-induced pruritus by epidural droperidol. Anesth Analg 90:638–41, 2000.CrossRefGoogle ScholarPubMed
Gunter, JB, McAuliffe, J, Gregg, T, et al. Continuous epidural butorphanol relieves pruritus associated with epidural morphine infusions in children. Paediatr Anaesth 10:167–72, 2000.CrossRefGoogle ScholarPubMed
Choi, JH, Lee, J, Choi, JH, Bishop, MJ. Epidural naloxone reduces pruritus and nausea without affecting analgesia by epidural morphine in bupivacaine. Can J Anaesth 47:33–7, 2000.CrossRefGoogle ScholarPubMed
Yeh, HM, Chen, LK, Lin, CJ, et al. Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. Anesth Analg 91:172–5, 2000.Google ScholarPubMed
Saiah, M, Borgeat, A, Wilder-Smith, OH, et al. Epidural-morphine-induced pruritus: propofol versus naloxone. Anesth Analg 78:1110–13, 1994.CrossRefGoogle ScholarPubMed
Dunteman, E, Karanikolas, M, Filos, KS. Transnasal butorphanol for the treatment of opioid-induced pruritus unresponsive to antihistamines. J Pain Symptom Manage 12:255–60, 1996.CrossRefGoogle ScholarPubMed
Katcher, J, Walsh, D. Opioid-induced itching: morphine sulfate and hydromorphone hydrochloride. J Pain Symptom Manage 17:70–2, 1999.CrossRefGoogle ScholarPubMed
Chaplan, SR, Duncan, SR, Brodsky, JB, Brose, WG. Morphine and hydromorphone epidural analgesia. A prospective, randomized comparison. Anesthesiology 77:1090–4, 1992.CrossRefGoogle ScholarPubMed
Cooper, A, White, D, Matthay, R. Drug-induced pulmonary disease. Am Rev Resp Dis 133:488–505, 1986.Google ScholarPubMed
Taff, RH. Pulmonary edema following naloxone administration in a patient without heart disease. Anesthesiology 59:576–7, 1983.CrossRefGoogle Scholar
Bruera, E, Miller, MJ. Non-cardiogenic pulmonary edema after narcotic treatment for cancer pain [see comments]. Pain 39:297–300, 1989.CrossRefGoogle Scholar
Bruera, E, Brenneis, C, Michaud, M, et al. Use of the subcutaneous route for the administration of narcotics in patients with cancer pain. Cancer 62:407–11, 1988.3.0.CO;2-T>CrossRefGoogle ScholarPubMed
Foley, K. The treatment of cancer pain. N Engl J Med 313:93, 1985.CrossRefGoogle ScholarPubMed
Bruera, E, Pereira, J. Acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain. Pain 69:199–201, 1997.CrossRefGoogle Scholar
Bruera, E, Miller, L, McCallion, J, et al. Cognitive failure in patients with terminal cancer: a prospective study. J Pain Symptom Manage 7:192–5, 1992.CrossRefGoogle ScholarPubMed
Stiefel, F, Fainsinger, R, Bruera, E. Acute confusional states in patients with advanced cancer. J Pain Symptom Manage 7:94–8, 1992.CrossRefGoogle ScholarPubMed
Fainsinger, R, Young, C. Cognitive failure in a terminally ill patient. J Pain Symptom Manage 6:492–4, 1991.CrossRefGoogle Scholar
Leipzig, RM, Goodman, H, Gray, G, et al. Reversible, narcotic-associated mental status impairment in patients with metastatic cancer. Pharmacology 35:47–54, 1987.CrossRefGoogle ScholarPubMed
Gaudreau, JD, et al. Psychoactive medications and risk of delirium in hospitalized cancer patients. J Clin Oncol 23:6712–18, 2005.CrossRefGoogle ScholarPubMed
Gaudreau, JD, et al. Opioid medications and longitudinal risk of delirium in hospitalized cancer patients. Cancer 109:2365–73, 2007.CrossRefGoogle ScholarPubMed
Gaudreau, JD, et al. Association between psychoactive medications and delirium in hospitalized patients: a critical review. Psychosomatics 46:302–16, 2005.CrossRefGoogle ScholarPubMed
Breitbart, W, Bruera, E, Chochinov, H, Lynch, M. Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer. J Pain Symptom Manage 10:131–41, 1995.CrossRefGoogle ScholarPubMed
Zacny, JP, Lichtor, JL, Thapar, P, et al. Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and morphine in healthy volunteers. J Pharmacol Exp Ther 270:579–88, 1994.Google ScholarPubMed
Zacny, JP, Lichtor, JL, Flemming, D, et al. A dose-response analysis of the subjective, psychomotor and physiological effects of intravenous morphine in healthy volunteers. J Pharmacol Exp Ther 268:1–9, 1994.Google ScholarPubMed
Clemons, M, Regnard, C, Appleton, T. Alertness, cognition and morphine in patients with advanced cancer. Cancer Treat Rev 22:451–68, 1996.CrossRefGoogle ScholarPubMed
Sjogren, P, Olsen, AK, Thomsen, AB, Dalberg, J. Neuropsychological performance in cancer patients: the role of oral opioids, pain and performance status. Pain 86:237–45, 2000.CrossRefGoogle ScholarPubMed
Galski, T, Williams, JB, Ehle, HT. Effects of opioids on driving ability. J Pain Symptom Manage 19:200–8, 2000.CrossRefGoogle ScholarPubMed
Crawford, RD, Baskoff, JD. Fentanyl-associated delirium in man. Anesthesiology 53:168–9, 1980.CrossRefGoogle ScholarPubMed
Bruera, E, Schoeller, T, Montejo, G. Organic hallucinosis in patients receiving high doses of opiates for cancer pain. Pain 48:397–9, 1992.CrossRefGoogle ScholarPubMed
Poyhia, R, Vainio, A, Kalso, E. A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 8:63–7, 1993.CrossRefGoogle ScholarPubMed
De Conno, F, Caraceni, A, Martini, C, et al. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 47:337–9, 1991.CrossRefGoogle ScholarPubMed
Paix, A, Coleman, A, Lees, J, et al. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain 63:263–9, 1995.CrossRefGoogle ScholarPubMed
Lawlor, P, Gagnon, B, Mancini, IL, et al. Phenomenology of delirium and its subtypes in advanced cancer patients: a prospective study [abstract]. J Palliat Care 14:106, 1998.Google Scholar
Lowe, GR. The phenomenology of hallucinations as an aid to differential diagnosis. Br J Psychiatry 123:621–33, 1973.CrossRefGoogle ScholarPubMed
Stiefel, F, Holland, J. Delirium in cancer patients. Int Psychogeriatr 3:333–6, 1991.CrossRefGoogle ScholarPubMed
Lawlor, PG, Gagnon, B, Mancini, IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 160:786–94, 2000.CrossRefGoogle ScholarPubMed
Massie, MJ, Holland, J, Glass, E. Delirium in terminally ill cancer patients. Am J Psychiatry 140:1048–50, 1983.Google ScholarPubMed
Lipowski, ZJ. Update on delirium. Psychiatr Clin North Am 15:335–46, 1992.Google ScholarPubMed
Bruera, E, Miller, MJ, Macmillan, K, Kuehn, N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 48:163–6, 1992.CrossRefGoogle ScholarPubMed
Nunez Olarthe, JM. Opioid-induced myoclonus. Eur J Palliat Care 2:146–50, 1996.Google Scholar
Marsden, CD. The nosology and pathophysiology of myoclonus. In: Marsden, CD, Fahn, S, eds. Movement disorders. London: Butterworth, 1982, pp 196–248.Google Scholar
Sagratella, S.Enkephalinase inhibition and hippocampal excitatory effects of exogenous and endogenous opioids. Prog Neuropsychopharmacol Biol Psychiatry 18:965–78, 1994.CrossRefGoogle ScholarPubMed
Shohami, E, Evron, S. Intrathecal morphine induces myoclonic seizures in the rat. Acta Pharmacol Toxicol (Copenh) 56:50–4, 1985.CrossRefGoogle ScholarPubMed
Sjogren, P, Dragsted, L, Christensen, CB. Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol Scand 37:780–2, 1993.CrossRefGoogle ScholarPubMed
Potter, JM, Reid, DB, Shaw, RJ, et al. Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs [see comments]. BMJ 299:150–3, 1989.CrossRefGoogle Scholar
Sjogren, P, Jonsson, T, Jensen, NH, et al. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 55:93–7, 1993.CrossRefGoogle ScholarPubMed
MacDonald, N, Der, L, Allan, S, Champion, P. Opioid hyperexcitability: the application of alternate opioid therapy. Pain 53:353–5, 1993.CrossRefGoogle ScholarPubMed
Babul, N, Darke, AC. Putative role of hydromorphone metabolites in myoclonus [letter]. Pain 51:260–1, 1992. [Published erratum appears in Pain 52:123, 1993.]CrossRefGoogle Scholar
Kaiko, RF, Foley, KM, Grabinski, PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 13:180–5, 1983.CrossRefGoogle ScholarPubMed
Hochman, MS. Meperidine-associated myoclonus and seizures in long-term hemodialysis patients [letter]. Ann Neurol 14:593, 1983.CrossRefGoogle Scholar
Danziger, LH, Martin, SJ, Blum, RA. Central nervous system toxicity associated with meperidine use in hepatic disease. Pharmacotherapy 14:235–8, 1994.Google ScholarPubMed
Rao, TL, Mummaneni, N, El Etr, AA. Convulsions: an unusual response to intravenous fentanyl administration. Anesth Analg 61:1020–1, 1982.CrossRefGoogle ScholarPubMed
Benthuysen, JL, Smith, NT, Sanford, TJ, et al. Physiology of alfentanil-induced rigidity. Anesthesiology 64:440–6, 1986.CrossRefGoogle ScholarPubMed
Bowdle, TA, Rooke, GA. Postoperative myoclonus and rigidity after anesthesia with opioids. Anesth Analg 78:783–6, 1994.CrossRefGoogle ScholarPubMed
Cartwright, PD, Hesse, C, Jackson, AO. Myoclonic spasms following intrathecal diamorphine. J Pain Symptom Manage 8:492–5, 1993.CrossRefGoogle ScholarPubMed
Szeto, HH, Inturrisi, CE, Houde, R, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med 86:738–41, 1977.CrossRefGoogle Scholar
Labella, FS, Pinsky, C, Havlicek, V. Morphine derivatives with diminished opiate receptor potency show enhanced central excitatory activity. Brain Res 174:263–71, 1979.CrossRefGoogle ScholarPubMed
Hagen, N, Thirlwell, MP, Dhaliwal, HS, et al. Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. J Clin Pharmacol 35:37–44, 1995.CrossRefGoogle ScholarPubMed
Babul, N, Darke, AC, Hagen, N. Hydromorphone metabolite accumulation in renal failure [letter]. J Pain Symptom Manage 10:184–6, 1995.CrossRefGoogle Scholar
,International Association for the Study of Pain SoT. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Pain Suppl 3:S1–226, 1986.Google Scholar
Sjogren, P, Jensen, NH, Jensen, TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 59:313–16, 1994.CrossRefGoogle ScholarPubMed
Stillman, MJ, Mouline, , Foley, K. Paradoxical pain following high-dose spinal morphine [abstract]. Pain Suppl 4:S389, 1987.CrossRefGoogle Scholar
Yaksh, TL, Harty, GJ. Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. J Pharmacol Exp Ther 244:501–7, 1988.Google ScholarPubMed
Gardell, LR, et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 22:6747–55, 2002.CrossRefGoogle ScholarPubMed
Folstein, MF, Folstein, SE, McHugh, PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–98, 1975.CrossRefGoogle Scholar
Breitbart, W, Rosenfeld, B, Roth, A, et al. The Memorial Delirium Assessment Scale [see comments]. J Pain Symptom Manage 13:128–37, 1997.CrossRefGoogle Scholar
Smith, MT, Watt, JA, Cramond, T. Morphine-3-glucuronide – a potent antagonist of morphine analgesia. Life Sci 47:579–85, 1990.CrossRefGoogle ScholarPubMed
Glare, PA, Walsh, TD, Pippenger, CE. Normorphine, a neurotoxic metabolite? [letter]. Lancet 335:725–6, 1990.CrossRefGoogle Scholar
Sjogren, P, Thunedborg, LP, Christrup, L, et al. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Acta Anaesthesiol Scand 42:1070–5, 1998.CrossRefGoogle ScholarPubMed
Mao, J, Price, DD, Mayer, DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci 14:2301–12, 1994.CrossRefGoogle ScholarPubMed
Borgbjerg, FM, Frigast, C. Segmental effects on motor function following different intrathecal receptor agonists and antagonists in rabbits. Acta Anaesthesiol Scand 41:586–94, 1997.CrossRefGoogle ScholarPubMed
Moss, JH. Anileridine-induced delirium. J Pain Symptom Manage 10:318–20, 1995.CrossRefGoogle ScholarPubMed
Eisendrath, SJ, Goldman, B, Douglas, J, et al. Meperidine-induced delirium. Am J Psychiatry 144:1062–5, 1987.Google ScholarPubMed
Parkinson, SK, Bailey, SL, Little, WL, Mueller, JB. Myoclonic seizure activity with chronic high-dose spinal opioid administration. Anesthesiology 72:743–5, 1990.CrossRefGoogle ScholarPubMed
Steinberg, RB, Gilman, , Johnson, F 3rd. Acute toxic delirium in a patient using transdermal fentanyl [see comments]. Anesth Analg 75:1014–16, 1992.CrossRefGoogle Scholar
Stoutz, ND, Bruera, E, Suarez-Almazor, M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10:378–84, 1995.CrossRefGoogle ScholarPubMed
Maddocks, I, Somogyi, A, Abbott, F, et al. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 12:182–9, 1996.CrossRefGoogle ScholarPubMed
Lawlor, P, Walker, P, Bruera, E, Mitchell, S. Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. J Pain Symptom Manage 13:356–61, 1997.CrossRefGoogle Scholar
Hagen, N, Swanson, R. Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies [see comments]. J Pain Symptom Manage 14:51–8, 1997.CrossRefGoogle Scholar
Mercadante, S.Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 86:1856–66, 1999.3.0.CO;2-G>CrossRefGoogle ScholarPubMed
Bruera, E, Franco, JJ, Maltoni, M, et al. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 10:287–91, 1995.CrossRefGoogle ScholarPubMed
Fainsinger, R, Schoeller, T, Bruera, E. Methadone in the management of cancer pain: a review. Pain 52:137–47, 1993.CrossRefGoogle ScholarPubMed
Bruera, E, Pereira, J, Watanabe, S, et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78:852–7, 1996.3.0.CO;2-T>CrossRefGoogle Scholar
Ripamonti, C, Zecca, E, Bruera, E. An update on the clinical use of methadone for cancer pain [see comments]. Pain 70:109–15, 1997.CrossRefGoogle Scholar
Choi, DW, Viseskul, V. Opioids and non-opioid enantiomers selectively attenuate N-methyl-D-aspartate neurotoxicity on cortical neurons. Eur J Pharmacol 155:27–35, 1988.CrossRefGoogle ScholarPubMed
Krug, M, Matthies, R, Wagner, M, Brodemann, R. Non-opioid antitussives and methadone differentially influence hippocampal long-term potentiation in freely moving rats. Eur J Pharmacol 231:355–361, 1993.CrossRefGoogle ScholarPubMed
Ebert, B, Andersen, S, Krogsgaard-Larsen, P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 187:165–8, 1995.CrossRefGoogle ScholarPubMed
Bruera, E, Sloan, P, Mount, B, et al. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group. J Clin Oncol 14:1713–17, 1996.CrossRefGoogle Scholar
Lawlor, P, Turner, K, Hanson, J, Bruera, E. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 72:79–85, 1997.CrossRefGoogle ScholarPubMed
Ripamonti, C, De Conno, F, Groff, L, et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 9:79–83, 1998.CrossRefGoogle ScholarPubMed
De Conno, F, Groff, L, Brunelli, C, et al. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 14:2836–42, 1996.CrossRefGoogle ScholarPubMed
Krames, ES, Gershow, J, Glassberg, A, et al. Continuous infusion of spinally administered narcotics for the relief of pain due to malignant disorders. Cancer 56:696–702, 1985.3.0.CO;2-8>CrossRefGoogle ScholarPubMed
Eisele, JH, Grigsby, EJ, Dea, G. Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report. Pain 49:231–2, 1992.CrossRefGoogle ScholarPubMed
Fainsinger, RL, Louie, K, Belzile, M, et al. Decreased opioid doses used on a palliative care unit. J Palliat Care 12:6–9, 1996.Google ScholarPubMed
Labrecque, G, Vanier, MC. Biological rhythms in pain and in the effects of opioid analgesics. Pharmacol Ther 68:129–47, 1995.CrossRefGoogle ScholarPubMed
Frederickson, RC, Burgis, V, Edwards, JD. Hyperalgesia induced by naloxone follows diurnal rhythm in responsivity to painful stimuli. Science 198:756–8, 1977.CrossRefGoogle ScholarPubMed
Sittl, R, Kamp, HD, Knoll, R. Zirkadiane rhythmik des Schmerzempfindens bei tumorpatienten. Nevenheilkunde 9:22–4, 1990.Google Scholar
Wilder-Smith, CH, Wilder-Smith, OH. Diurnal patterns of pain in cancer patients during treatment with long-acting opioid analgesics. In: Smolensky, MH, Labrecque, G, Reinberg, A, et al., eds. Proceedings of the 5th International Conference on Biological Rhythms and Medications. Amelia Island, FL, 1992, pp xiii–6.Google Scholar
Vanier, MC, Labrecque, G, Lepage-Savary, D. Temporal changes in the hydromorphone analgesia in cancer patients. In: Smolensky, MH, Labrecque, G, Reinberg, A, et al., eds. Proceedings of the 5th International Conference on Biological Rhythms and Medications. Amelia Island, FL, 1992.Google Scholar
Citron, ML, Kalra, JM, Seltzer, VL, et al. Patient-controlled analgesia for cancer pain: a long-term study of inpatient and outpatient use. Cancer Invest 10:335–41, 1992.CrossRefGoogle ScholarPubMed
Bruera, E, Macmillan, K, Kuehn, N, Miller, MJ. Circadian distribution of extra doses of narcotic analgesics in patients with cancer pain: a preliminary report. Pain 49:311–14, 1992.CrossRefGoogle ScholarPubMed
Bruera, E, Fainsinger, R, Spachynski, K, et al. Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J Clin Oncol 13:1520–7, 1995.CrossRefGoogle ScholarPubMed
Fainsinger, RL, MacEachern, T, Miller, MJ, et al. The use of hypodermoclysis for rehydration in terminally ill cancer patients. J Pain Symptom Manage 9:298–302, 1994.CrossRefGoogle ScholarPubMed
Ashby, M, Fleming, B, Wood, M, Somogyi, A. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J Pain Symptom Manage 14:157–67, 1997.CrossRefGoogle ScholarPubMed
Breitbart, W, Marotta, R, Platt, MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 153:231–7, 1996.Google ScholarPubMed
Settle, EC Jr, Ayd, FJ Jr. Haloperidol: a quarter century of experience. J Clin Psychiatry 44:440–8, 1983.Google ScholarPubMed
Coyle, N, Breitbart, W, Weaver, S, Portenoy, R. Delirium as a contributing factor to “crescendo” pain: three case reports. J Pain Symptom Manage 9:44–7, 1994.CrossRefGoogle ScholarPubMed
Fromm, GH. Baclofen as an adjuvant analgesic. J Pain Symptom Manage 9:500–9, 1994.CrossRefGoogle ScholarPubMed
Luo, L, Puke, MJ, Wiesenfeld-Hallin, Z. The effects of intrathecal morphine and clonidine on the prevention and reversal of spinal cord hyperexcitability following sciatic nerve section in the rat. Pain 58:245–52, 1994.CrossRefGoogle ScholarPubMed
Waldman, HJ. Centrally acting skeletal muscle relaxants and associated drugs. J Pain Symptom Manage 9:434–41, 1994.CrossRefGoogle ScholarPubMed
Gear, RW, Miaskowski, C, Heller, PH, et al. Benzodiazepine mediated antagonism of opioid analgesia. Pain 71:25–9, 1997.CrossRefGoogle ScholarPubMed
Lipowski, ZJ. Somatization: the concept and its clinical application. Am J Psychiatry 145:1358–68, 1988.Google ScholarPubMed
Massie, MJ. Somatoform disorder and cancer. In: Holland, JC, Rowlands, JH, eds. Handbook of psychooncology. Oxford: Oxford University Press, 1989, pp 317–19.Google Scholar
Wickramasekera, IE. Somatization. Concepts, data, and predictions from the high risk model of threat perception. J Nerv Ment Dis 183:15–23, 1995.CrossRefGoogle ScholarPubMed
Katon, W. Depression: relationship to somatization and chronic medical illness. J Clin Psychiatry 45(3 Pt 2):4–12, 1984.Google ScholarPubMed
Katon, W, Kleinman, A, Rosen, G. Depression and somatization: a review. Part II. Am J Med 72:241–7, 1982.CrossRefGoogle ScholarPubMed
Marsden, CD. Hysteria – a neurologist's view. Psychol Med 16:277–88, 1986.CrossRefGoogle ScholarPubMed
Bass, C, Wade, C, Hand, D, Jackson, G. Patients with angina with normal and near normal coronary arteries: clinical and psychosocial state 12 months after angiography. Br Med J (Clin Res Ed) 287:1505–8, 1983.CrossRefGoogle ScholarPubMed
Fobair, P, Hoppe, RT, Bloom, J, et al. Psychosocial problems among survivors of Hodgkin's disease. J Clin Oncol 4:805–14, 1986.CrossRefGoogle ScholarPubMed
Devlen, J, Maguire, P, Phillips, P, Crowther, D. Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study. Br Med J (Clin Res Ed) 295:955–7, 1987.CrossRefGoogle ScholarPubMed
Loge, JH, Abrahamsen, AF, Ekeberg, O, et al. Psychological distress after cancer cure: a survey of 459 Hodgkin's disease survivors. Br J Cancer 76:791–6, 1997.CrossRefGoogle ScholarPubMed
Chaturvedi, SK, Hopwood, P, Maguire, P. Non-organic somatic symptoms in cancer. Eur J Cancer 29A:1006–8, 1993.CrossRefGoogle Scholar
Cherny, NI, Coyle, N, Foley, KM. Suffering in the advanced cancer patient: a definition and taxonomy. J Palliat Care 10:57–70, 1994.Google ScholarPubMed
Breitbart, W.Cancer pain management guidelines: implications for psycho-oncology [abstract]. Psychooncology 3:103–8, 1994.CrossRefGoogle Scholar
Bruera, E, Watanabe, S. New developments in the assessment of pain in cancer patients. Supportive Care Cancer 2:312–18, 1994.CrossRefGoogle ScholarPubMed
Bruera, E, Macmillan, K, Hanson, J, MacDonald, RN. The Edmonton staging system for cancer pain: preliminary report. Pain 37:203–9, 1989.CrossRefGoogle ScholarPubMed
Vigano, A, Watanabe, S, Bruera, E. Methylphenidate for the management of somatization in terminal cancer patients. J Pain Symptom Manage 10:167–70, 1995.CrossRefGoogle ScholarPubMed
Watanabe, S, Carmody, D, Bruera, E. Successful multidimensional intervention in a patient with intractable neuropathic cancer pain. J Palliat Care 13:52–4, 1997.Google Scholar
Robinson, K, Bruera, E. The management of pain in patients with advanced cancer: the importance of multidimensional assessments. J Palliat Care 11:51–3, 1995.Google ScholarPubMed
Dalton, JA, Feuerstein, M. Fear, alexithymia and cancer pain. Pain 38:159–70, 1989.CrossRefGoogle ScholarPubMed
Turk, DC, Sist, TC, Okifuji, A, et al. Adaptation to metastatic cancer pain, regional/local cancer pain and non-cancer pain: role of psychological and behavioral factors. Pain 74:247–56, 1998.CrossRefGoogle ScholarPubMed
Chapman, CR, Gavrin, J. Suffering and its relationship to pain [see comments]. J Palliat Care 9:5–13, 1993.Google Scholar
Poulin, C, Webster, I, Single, E. Alcohol disorders in Canada as indicated by the CAGE questionnaire [see comments]. CMAJ 157:1529–35, 1997.Google Scholar
O'Connor, PG, Schottenfeld, RS. Patients with alcohol problems [see comments]. N Engl J Med 338:592–602, 1998.CrossRefGoogle Scholar
Regier, DA, Myers, JK, Kramer, M, et al. The NIMH Epidemiologic Catchment Area program. Historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 41:934–41, 1984.CrossRefGoogle ScholarPubMed
Savage, SR. Long-term opioid therapy: assessment of consequences and risks. J Pain Symptom Manage 11:274–86, 1996.CrossRefGoogle ScholarPubMed
Lehman, WE, Barrett, ME, Simpson, DD. Alcohol use by heroin addicts 12 years after drug abuse treatment. J Stud Alcohol 51:233–44, 1990.CrossRefGoogle ScholarPubMed
Moore, RD, Bone, LR, Geller, G, et al. Prevalence, detection, and treatment of alcoholism in hospitalized patients [see comments]. JAMA 261:403–7, 1989.CrossRefGoogle Scholar
Ginsburg, ML, Quirt, C, Ginsburg, AD, MacKillop, WJ. Psychiatric illness and psychosocial concerns of patients with newly diagnosed lung cancer [see comments]. CMAJ 152:701–8, 1995.Google Scholar
Bruera, E, Moyano, J, Seifert, L, et al. The frequency of alcoholism among patients with pain due to terminal cancer. J Pain Symptom Manage 10:599–603, 1995.CrossRefGoogle ScholarPubMed
McCorquodale, S, De Faye, B, Bruera, E. Pain control in an alcoholic cancer patient. J Pain Symptom Manage 8:177–80, 1993.CrossRefGoogle Scholar
Passik, SD, Portenoy, RK, Ricketts, PL. Substance abuse issues in cancer patients. Part 2: evaluation and treatment. Oncology (Huntingt) 12:729–34, 1998.Google ScholarPubMed
Ewing, JA. Detecting alcoholism. The CAGE questionnaire. JAMA 252:1905–7, 1984.CrossRefGoogle ScholarPubMed
Bruera, E, MacDonald, S. Audit methods: the Edmonton Symptom Assessment System. In: Higginson, I, ed. Clinical audit in palliative care. Oxford: Radcliffe Medical Press, 1993, pp 61–77.Google Scholar
Risdahl, JM, Khanna, KV, Peterson, PK, Molitor, TW. Opiates and infection. J Neuroimmunol 83:4–18, 1998.CrossRefGoogle ScholarPubMed
Eisenstein, TK, Hilburger, ME. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J Neuroimmunol 83:36–44, 1998.CrossRefGoogle ScholarPubMed
Grossman, A, Besser, GM. Opiates control ACTH through a noradrenergic mechanism. Clin Endocrinol 17:287–90, 1982.CrossRefGoogle ScholarPubMed
Volavka, J, Bauman, J, Pevnick, J, et al. Short-term hormonal effects of naloxone in man. Psychoneuroendocrinology 5:225–34, 1980.CrossRefGoogle ScholarPubMed
Morley, JE, Baranetsky, NG, Wingert, TD, et al. Endocrine effects of naloxone-induced opiate receptor blockade. J Clin Endocrinol Metab 50:251–7, 1980.CrossRefGoogle ScholarPubMed
Allolio, B, Winkelmann, W, Hipp, FX, et al. Effects of a met-enkephalin analog on adrenocorticotropin (ACTH), growth hormone, and prolactin in patients with ACTH hypersecretion. J Clin Endocrinol Metab 55:1–7, 1982.CrossRefGoogle Scholar
Pfeiffer, A, Herz, A. Endocrine actions of opioids. Horm Metab Res 16:386–97, 1984.CrossRefGoogle ScholarPubMed
Abs, R, Verhelst, J, Maeyaert, J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 85:2215–22, 2000.CrossRefGoogle ScholarPubMed
Zitzmann, M, Nieschlag, E. Hormone substitution in male hypogonadism. Mol Cell Endocrinol 161:73–88, 2000.CrossRefGoogle ScholarPubMed
Cuneo, RC, et al. The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf) 37:387–97, 1992.CrossRefGoogle ScholarPubMed
McGauley, GA. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand Suppl 356:70–2, 1989; discussion 73–4.CrossRefGoogle ScholarPubMed
McGauley, G. The psychological consequences and quality of life in adults with growth hormone deficiency. Growth Horm IGF Res 10(Suppl B):S63–8, 2000.CrossRefGoogle ScholarPubMed
Bair, MJ, et al. Depression and pain comorbidity: a literature review. Arch Intern Med 163:2433–45, 2003.CrossRefGoogle ScholarPubMed
Ambler, N, et al. Sexual difficulties of chronic pain patients. Clin J Pain 17:138–45, 2001.CrossRefGoogle ScholarPubMed
Rajagopal, A, et al. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 100:851–8, 2004.CrossRefGoogle ScholarPubMed
Schneider, J.Hypogonadism in men treated with chronic opioids. Arch Phys Med Rehabil 89:1414, 2008; author reply 1414.CrossRefGoogle ScholarPubMed
Fraser, , Morrison, D, Morley-Forster, P, et al. Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes 2008 [Epub ahead of print].CrossRefGoogle ScholarPubMed
Yardeni, IZ, Beilin, B, Mayburd, E, et al. Relationship between fentanyl dosage and immune function in the post-operative period. J Opioid Manag 4:27–33, 2008.CrossRefGoogle Scholar
Daniell, HW. Hypogonadism in men consuming sustain-action oral opioids. J Pain 3:377–84, 2002.CrossRefGoogle ScholarPubMed
Strasser, F, et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 107:2949–57, 2006.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×